| 1 |
33230698 | Fibroblast growth factor 23-Klotho and hypertension: experimental and clinical mechanisms. | 2021 Oct |
1 |
| 2 |
33767635 | An Overview of FGF-23 as a Novel Candidate Biomarker of Cardiovascular Risk. | 2021 |
1 |
| 3 |
34203792 | The Metabolic Bone Disease X-linked Hypophosphatemia: Case Presentation, Pathophysiology and Pharmacology. | 2021 Jun 15 |
5 |
| 4 |
34504604 | Crosstalk of fibroblast growth factor 23 and anemia-related factors during the development and progression of CKD (Review). | 2021 Oct |
1 |
| 5 |
34519274 | Low serum 1,25(OH)2D3 in end-stage renal disease: is reduced 1α-hydroxylase the only problem? | 2021 Oct 11 |
2 |
| 6 |
34757587 | Regulation of FGF23: Beyond Bone. | 2021 Dec |
1 |
| 7 |
31792685 | FGF23 and Bone and Mineral Metabolism. | 2020 |
2 |
| 8 |
31965544 | New Developments in the Treatment of X-Linked Hypophosphataemia: Implications for Clinical Management. | 2020 Apr |
2 |
| 9 |
32140858 | Phosphate-sensing and regulatory mechanism of FGF23 production. | 2020 Jul |
1 |
| 10 |
33204932 | X-Linked Hypophosphatemia: A New Era in Management. | 2020 Dec 1 |
2 |
| 11 |
31218207 | Regulation of Fibroblast Growth Factor 23 by Iron, EPO, and HIF. | 2019 Mar |
2 |
| 12 |
31369697 | Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X-Linked Hypophosphatemia: A Phase 3, Single-Arm, International Trial. | 2019 Dec |
1 |
| 13 |
29446010 | Phosphaturic mesenchymal tumors: what an endocrinologist should know. | 2018 Oct |
1 |
| 14 |
29515522 | Targeting Fibroblast Growth Factor 23 Signaling with Antibodies and Inhibitors, Is There a Rationale? | 2018 |
1 |
| 15 |
29669938 | Canagliflozin triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study. | 2018 Apr 19 |
1 |
| 16 |
30041203 | Intravenous Maxacalcitol Therapy Correlates with Serum Fibroblast Growth Factor 23 Levels in Hemodialysis Patients Independent of Serum Phosphate or Calcium Levels. | 2018 |
1 |
| 17 |
30236113 | Serum phosphate and phosphate-regulatory hormones in COPD patients. | 2018 Sep 20 |
2 |
| 18 |
30513912 | The Emerging Role of Nutritional Vitamin D in Secondary Hyperparathyroidism in CKD. | 2018 Dec 3 |
2 |
| 19 |
28713755 | Tumor-induced Osteomalacia: A Sherlock Holmes Approach to Diagnosis and Management. | 2017 Jan-Jun |
1 |
| 20 |
29271617 | Effects of Single Vitamin D₃ Injection (200,000 Units) on Serum Fibroblast Growth Factor 23 and Sclerostin Levels in Subjects with Vitamin D Deficiency. | 2017 Dec |
3 |
| 21 |
26073451 | Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) in the first multiple ascending-dose trial treating adults with X-linked hypophosphatemia. | 2016 Feb |
2 |
| 22 |
26459742 | Therapeutic effect of CNP on renal osteodystrophy by antagonizing the FGF-23/MAPK pathway. | 2016 |
1 |
| 23 |
26813504 | [Phosphate metabolism and iron deficiency]. | 2016 Feb |
1 |
| 24 |
27012053 | The Superiority of AN69ST Membrane in the Adsorption of Fibroblast Growth Factor-23. | 2016 |
1 |
| 25 |
27440690 | Fibroblast growth factor-23 and phosphorus related factors in young Japanese women: a cross-sectional study. | 2016 |
1 |
| 26 |
27471744 | A study on the association of serum fibroblast growth factor-23 with various indices of chronic kidney disease patients not yet on dialysis. | 2016 |
2 |
| 27 |
27679714 | Serum FGF23 levels may not be associated with serum phosphate and 1,25-dihydroxyvitamin D levels in patients with Fanconi syndrome-induced hypophosphatemia. | 2016 Oct |
1 |
| 28 |
25445451 | FGF23 gene variation and its association with phosphate homeostasis and bone mineral density in Finnish children and adolescents. | 2015 Feb |
2 |
| 29 |
25451947 | Serum free 1,25-dihydroxy-vitamin D is more closely associated with fibroblast growth factor 23 than other vitamin D forms in chronic dialysis patients. | 2015 Jan 15 |
1 |
| 30 |
25656441 | Hyperphosphatemic familial tumoral calcinosis: genetic models of deficient FGF23 action. | 2015 Apr |
1 |
| 31 |
25926572 | [Vascular Calcification - Pathological Mechanism and Clinical Application - . Regulation of mineral metabolism and mineralization by FGF23]. | 2015 May |
2 |
| 32 |
27194998 | Elevated Fibroblast Growth Factor 23 Concentration: Prediction of Mortality among Chronic Kidney Disease Patients. | 2015 Dec |
2 |
| 33 |
24258305 | Predictors of intact and C-terminal fibroblast growth factor 23 in Gambian children. | 2014 |
1 |
| 34 |
24848934 | Anti-fibroblast growth factor 23 antibody therapy. | 2014 Jul |
1 |
| 35 |
25062462 | Lack of FGF23 response to acute changes in serum calcium and PTH in humans. | 2014 Oct |
3 |
| 36 |
25352227 | Bone mineralization is regulated by signaling cross talk between molecular factors of local and systemic origin: the role of fibroblast growth factor 23. | 2014 Nov-Dec |
2 |
| 37 |
25423921 | [New Developments in CKD-MBD. Development and progression of CKD-MBD in predialysis period -when and how?]. | 2014 Dec |
1 |
| 38 |
22886720 | Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes. | 2013 Jan |
1 |
| 39 |
22986488 | Ultraviolet B activated 1,25(OH)(2)D affects the level of fibroblast growth factor-23 in human. | 2013 |
1 |
| 40 |
23180879 | Fibroblast growth factor 23 and soluble klotho in children with chronic kidney disease. | 2013 Jan |
1 |
| 41 |
23263654 | 1,25-dihydroxyvitamin D(3) regulation of fibroblast growth factor-23 expression in bone cells: evidence for primary and secondary mechanisms modulated by leptin and interleukin-6. | 2013 Apr |
1 |
| 42 |
25019032 | Fibroblast growth factor 23 and 25-hydroxyvitamin D levels are associated with estimated glomerular filtration rate decline. | 2013 Dec |
1 |
| 43 |
21932165 | The role of vitamin D in the FGF23, klotho, and phosphate bone-kidney endocrine axis. | 2012 Mar |
1 |
| 44 |
22140123 | Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol. | 2012 Jun |
2 |
| 45 |
22167381 | The expanding family of hypophosphatemic syndromes. | 2012 Jan |
1 |
| 46 |
22249518 | Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. | 2012 Jan 17 |
2 |
| 47 |
22293059 | A randomised clinical study of alfacalcidol and paricalcitol. | 2012 Feb |
1 |
| 48 |
22362065 | Combined use of vitamin D status and FGF23 for risk stratification of renal outcome. | 2012 May |
1 |
| 49 |
22393163 | 1,25-Dihydroxyvitamin D(3) and extracellular inorganic phosphate activate mitogen-activated protein kinase pathway through fibroblast growth factor 23 contributing to hypertrophy and mineralization in osteoarthritic chondrocytes. | 2012 Mar |
3 |
| 50 |
22396168 | FGF23 as a novel therapeutic target. | 2012 |
1 |